Amgen Announces Positive Results Of Phase 3 Study For Treatment Of Severe Oral Mucositis

5/28/2003 Thousand Oaks, Calif. Amgen Amgen (Nasdaq: AMGN), announced today that rHu-KGF decreased the duration and incidence of severe oral mucositis in a phase 3 study of patients undergoing bone marrow transplantation treatment for hematologic malignancies such as lymphoma, multiple myeloma, and leukemia. Natural keratinocyte growth factor stimulates the growth and development of epithelial cells, including the cells that line the gastrointestinal tract. Amgen is studying a recombinant human keratinocyte growth factor (rHu-KGF) to protect epithelial cells from injury caused by anti-tumor treatments such as radiation and chemotherapy. Mucositis is a painful and debilitating condition in which patients experience severe mouth ulcerations that can make swallowing difficult or impossible. Preliminary results from the Phase 3 randomized, double blind trial were positive on all end-points showing highly significant decrease in both the duration and incidence of severe mucositis. The trial also showed that KGF was well tolerated. Roger Perlmutter, Amgen's executive vice president of research and development, said: There is no currently approved therapy to treat oral mucositis, a sometimes devastating complication of cancer chemotherapy. We are looking forward to discussing our phase 3 results that address this critical unmet medical need with regulatory agencies in the near future. Amgen will now investigate the efficacy and safety of KGF in other patient populations who suffer from high rates of mucositis associated with their anti-tumor treatments. OCF NOTE: OCF is excited about Amgen bringing this product to market and investigating is efficacy in the treatment of oral mucositis, a considerable problem for [...]

2009-03-22T20:14:26-07:00May, 2003|Archive|

Harbury Chef Beats The Odds With New Book

5/27/2003 London, United Kingdom CNN Europe A renowned chef who was told by doctors to stop working and enjoy life after being diagnosed with secondary cancer is hoping his new recipe book will help others. Guiseppe Iacaruso, known as Pino, went through major facial surgery in 1996 to beat a second attack of mouth cancer against all the odds and is still free of the disease seven years on.The esteemed Harbury chef has now combined his talents with food, words and watercolours in his first book, Flavours of Rosello, with a share of the profits going to the Get A-Head charity appeal. The 55-year-old of Penelope Close said: "It's wonderful. I never expected it to look so lovely." Mr Iacaruso has cooked for several members of the royal family including the Queen, the late Princess Margaret and Prince and Princess Michael of Kent, has served in the kitchens of the Italian and Finnish Embassies and worked in some of the best hotels in the country during his career. The book is based on his childhood memories of the little Italian village of Rosello in the 1950s and 60s, and is introduced by Princess Michael of Kent. Packed with recipes and illustrated by Mr Iacaruso's own watercolours and sketches by friend George Corbett, the enchanting book offers a month-by-month account of what life was like as he grew up in the Abruzzo region famed for its chefs. The idea for the memoirs came from his wife, Caroline, who he married in [...]

2009-03-22T20:15:36-07:00May, 2003|Archive|

PET can assess efficacy of cancer treatment

5/10/2003 New York Karla Gale Reuters Health News British researchers report that positron emission tomography (PET) can measure levels of thymidine in tumors, an indicator of patient response to chemotherapy with agents that inhibit thymidylate synthase. Their findings, published in the May 7th issue of the Journal of the National Cancer Institute, show that PET can be used broadly to "track cancer treatment efficacy without the need for repeated tissue biopsies," coauthor Dr. Pat M. Price told Reuters Health. Not only will individual treatment assessment permit early recognition of treatment failure, such strategies should accelerate the rate at which clinical trials can be completed, she added. Thymidylate synthase inhibitors such as 5-fluorouracil, 5-fluorodeoxyuridine and nolatrexed dihydrochloride (AG337; Agouron Pharmaceuticals, San Diego) target a key enzyme in the biosynthetic pathway of thymidine nucleotides used in the synthesis of DNA, Dr. Price and colleagues explain. Resistance to these agents involves a salvage pathway by which depleted thymidine levels are reversed by increasing exogenous thymidine uptake, which makes thymidine a valuable marker of tumor proliferation. Plasma levels of deoxyuridine, which increase following thymidylate synthase inhibition, do not reflect thymidylate synthase inhibition in specific tissues. Dr. Price, of Christie Hospital NHS Trust in Manchester, UK, and her associates set out to evaluate PET scanning with radiolabeled thymidine as a means of measuring tumor thymidine incorporation, an indicator of thymidylate synthase inhibition. They conducted PET scanning in patients with advanced gastrointestinal cancer. Five patients enrolled in a phase I trial of AG337 were scanned 4 [...]

2009-03-22T20:10:09-07:00May, 2003|Archive|
Go to Top